174 related articles for article (PubMed ID: 1721328)
1. Categorizing receptor-signaling pathways with FK 506 and rapamycin.
Hultsch T; Hohman RJ
Transplant Proc; 1991 Dec; 23(6):2961-3. PubMed ID: 1721328
[No Abstract] [Full Text] [Related]
2. FK 506 and rapamycin: molecular probes of T-lymphocyte activation.
Bierer BE; Jin YJ; Fruman DA; Calvo V; Burakoff SJ
Transplant Proc; 1991 Dec; 23(6):2850-5. PubMed ID: 1721296
[No Abstract] [Full Text] [Related]
3. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes.
Dumont FJ; Kastner C; Iacovone F; Fischer PA
J Pharmacol Exp Ther; 1994 Jan; 268(1):32-41. PubMed ID: 7507994
[TBL] [Abstract][Full Text] [Related]
4. Modes of action of FK506, cyclosporin A, and rapamycin.
Morris R
Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
[No Abstract] [Full Text] [Related]
5. Immunophilin-ligand complexes as probes of intracellular signaling pathways.
Schreiber SL; Liu J; Albers MW; Karmacharya R; Koh E; Martin PK; Rosen MK; Standaert RF; Wandless TJ
Transplant Proc; 1991 Dec; 23(6):2839-44. PubMed ID: 1721293
[No Abstract] [Full Text] [Related]
6. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
Bierer BE
Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
[No Abstract] [Full Text] [Related]
7. Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner.
Su MS; Semerjian A
Transplant Proc; 1991 Dec; 23(6):2912-5. PubMed ID: 1721310
[No Abstract] [Full Text] [Related]
8. Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties?
Schreier MH; Baumann G; Zenke G
Transplant Proc; 1993 Feb; 25(1 Pt 1):502-7. PubMed ID: 7679818
[No Abstract] [Full Text] [Related]
9. Chemistry and biology of the immunophilins and their immunosuppressive ligands.
Schreiber SL
Science; 1991 Jan; 251(4991):283-7. PubMed ID: 1702904
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of rapamycin (Sirolimus, Rapamune).
Molnar-Kimber KL
Transplant Proc; 1996 Apr; 28(2):964-9. PubMed ID: 8623482
[No Abstract] [Full Text] [Related]
11. Cyclosporin A, FK506, and rapamycin: binding to immunophilins and biological action.
Bierer BE
Chem Immunol; 1994; 59():128-55. PubMed ID: 7524531
[No Abstract] [Full Text] [Related]
12. Site of action of cyclosporine and FK 506 in the pathways of communication between the T-lymphocyte antigen receptor and the early activation genes.
Ullman KS; Flanagan WM; Cothesy B; Kuo P; Northrop JP; Crabtree GR
Transplant Proc; 1991 Dec; 23(6):2845. PubMed ID: 1721294
[No Abstract] [Full Text] [Related]
13. A nonimmunosuppressive triene-modified rapamycin analog is a potent inhibitor of peptidyl prolyl cis-trans isomerase.
Ocain TD; Longhi D; Steffan RJ; Caccese RG; Sehgal SN
Biochem Biophys Res Commun; 1993 May; 192(3):1340-6. PubMed ID: 7685167
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive macrolides.
Stütz A
Transplant Proc; 1992 Aug; 24(4 Suppl 2):22-5. PubMed ID: 1379762
[No Abstract] [Full Text] [Related]
15. Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and rapamycin.
Siekierka JJ
Immunol Res; 1994; 13(2-3):110-6. PubMed ID: 7539823
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction.
Sigal NH; Dumont FJ
Annu Rev Immunol; 1992; 10():519-60. PubMed ID: 1375473
[TBL] [Abstract][Full Text] [Related]
17. The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506.
Nakajima H; Oka T
Transplant Proc; 1996 Apr; 28(2):1052-5. PubMed ID: 8623224
[No Abstract] [Full Text] [Related]
18. In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use.
Morris RE
Transplant Proc; 1991 Dec; 23(6):2722-4. PubMed ID: 1721257
[No Abstract] [Full Text] [Related]
19. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor.
Dilling MB; Dias P; Shapiro DN; Germain GS; Johnson RK; Houghton PJ
Cancer Res; 1994 Feb; 54(4):903-7. PubMed ID: 7508822
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin].
Rondeau E
Nephrologie; 1992; 13(3):137. PubMed ID: 1379348
[No Abstract] [Full Text] [Related]
[Next] [New Search]
